Avadel Pharmaceuticals PLC

Avadel Pharmaceuticals — Q4 2024 Earnings Presentation

16 slides from Avadel Pharmaceuticals's earnings presentation, Jan 8, 2025

  1. Slide 1: Fourth Quarter and Full Year 2024 Earnings

    AVADEL Pharmaceuticals plc (NASDAQ: AVDL) Fourth Quarter and Full Year 2024 Earnings

  2. Slide 2: Transforming Medicines to Transform Lives

    A BIOPHARMACEUTICAL COMPANY FOCUSED ON TRANSFORMING MEDICINES TO TRANSFORM LIVES 2

  3. Slide 3: Safe Harbor Statements

    Safe Harbor Statements This presentation may include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements relate to our future expectations, beliefs, plans, strategies, obje

  4. Slide 4: Avadel at a glance

    Corporate Headquarters Publicly traded on Dublin, Ireland NASDAQ since 1996 : AVDL 2,500 Patients on therapy* St. Louis, US Operations Missouri Deep, wholly-owned pipeline with Management team with extensive numerous expansion opportunities commercial experience in rare and 30 Orange book listed pat

  5. Slide 5: Launch to Date

    Launch to Date1 ~$197 Net revenue ($M) 2,500 Patients on therapy Since its launch in June 2023, LUMRYZ has seen LUMRYZ Net Patient consistent patient uptake ~3:1 Adds vs Twice Nightly Mixed-Salt Oxybates Since July 2023 1) Figures as of December 31, 2024 5

  6. Slide 6: LUMRYZ Peak Sales Opportunity is >$1B For Narcolepsy

    LUMRYZ Peak Sales Opportunity is >$1B For Narcolepsy >14,000 patients Over 50,000 oxybate-eligible >14,000 treated with first patients with narcolepsy patients generation oxybates >15,000 patients 25,000+ patients >50,000 that discontinued first 8,000 reimbursed patients on therapy achieves $1B in s

  7. Slide 7: Targeted initial launch strategy has resulted in meaningful penetration with early adopters

    Targeted initial launch strategy has resulted in meaningful penetration with early adopters EARLY LAUNCH STRATEGY: Early Adopters Represent 2/3 of total Targeted and focused (~25% of oxybate market) LUMRYZ patient starts 2025 LAUNCH STRATEGY: Capitalize on momentum Remaining Represent 1/3 of total w

  8. Slide 8: Our Launch Strategy Has Built a Strong Foundation for Continued Growth

    Our Launch Strategy Has Built a Strong Foundation for Continued Growth Targeted Market leadership investments to in new-to-brand Deliver positive expand demand and patients while cash flow optimize patient generating growth generation in experience from all patient 2025 segments 8

  9. Slide 9: Investment Strategy Builds on Positive Momentum LUMRYZ

    Expanding customer-facing teams to enable greater engagement with patients, providers, Investment Strategy and caregivers Builds on Positive Deploying higher-touch, more frequent, and Momentum LUMRYZ more personalized support services to better aid patient transitions to LUMRYZ has Generated with Pa

  10. Slide 10: Idiopathic Hypersomnia and REVITALYZ Phase 3 trial

    Idiopathic hypersomnia (IH) is a rare sleep disorder characterized by excessive daytime sleepiness (EDS) not attributable to any other <10% treated medical conditions; 42,000 patients with the only FDA diagnosed with IH in US approved oxybate treatment Initiated REVITALYZ Phase 3 trial to evaluate t

  11. Slide 11: Advancing Innovative and Transformative Sleep Medicine Pipeline

    Advancing Innovative and Transformative Sleep Medicine Pipeline REGULATORY PROGRAM INDICATION PRECLINICAL PHASE 1 PHASE 2 PHASE 3 COMMERCIAL MAJOR MILESTONES REVIEW Narcolepsy – Excessive Daytime Received FDA approval Sleepiness (EDS) and ODE in May 2023; and/or Cataplexy in launched in June 2023 Ad

  12. Slide 12: Financials

    Financials

  13. Slide 13: Financial Summary

    Financial Summary1 Q4 FULL YEAR ($ in millions) 2023 2024 2023 2024 Product Revenue $19.5 $50.4 $28.0 $169.1 Operating Expenses $43.7 $48.9 $165.0 $196.2 Operating Loss ($24.9) ($3.3) ($137.8) ($42.4) Cash, Cash Equivalents & $105.1 $73.8 Marketable Securities 1 – Refer to Forms 10-K for the years e

  14. Slide 14: GAAP vs. Non-GAAP Reconciliation

    GAAP vs. Non-GAAP Reconciliation Q4 FULL YEAR ($ in millions) 2023 2024 2023 2024 GAAP Operating Loss ($24.9) ($3.3) ($137.8) ($42.4) Stock Based Compensation $3.5 $4.1 $15.8 $20.4 Depreciation & Amortization 1 $1.1 $1.0 $4.3 $4.2 Transaction Costs 2 $- $- $- $5.5 Non-GAAP Operating (Loss) ($20.3) $

  15. Slide 15: 2025 Guidance

    2025 Guidance Revenue $240 - $260M Cash Operating Expenses $180 - $200M Cash Flow $20 - $40M Patients on Therapy at 12/31/2025 3.3 – 3.5K 15

  16. Slide 16: A Leader in the Sleep Space With Substantial Growth Opportunities

    A Leader in the Sleep Space With Substantial Growth Opportunities Meeting Unmet Needs in Narcolepsy 94%1 of patients prefer LUMRYZ over first-generation oxybates due to once at night dosing; awarded Orphan Drug Exclusivity for major contribution to patient care Opportunity For Growth In Narcolepsy $

Avadel Pharmaceuticals — Q4 2024 Earnings Presentation on 6ix